Company / Return on Equity (ROE)
Bluejay Diagnostics, Inc. Return on Equity (ROE) History
FY2022-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-343.8%
FY2023
5-year range
-343.8% / -80.5%
FY2022-FY2023
Trend
-326.9%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Bluejay Diagnostics, Inc. reports negative total equity of -343.8% in FY2023. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-343.8% in FY2023.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2023, return on equity (roe) decreased 326.9% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -10.44 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2023 | -343.8% | -326.9% |
| FY2022 | -80.5% | - |
As of FY2023 · SEC Form 10-K · Last checked Jun 22, 2026